Theodore L. Schreiber
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Theodore L. Schreiber has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Ahmad Munir
Wayne State University/Detroit Medical Center, Heart Hospital, Detroit, Michigan
1 shared publication- Alexandros Briasoulis
Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
1 shared publication Amir Kaki
Wayne State University/Detroit Medical Center, Heart Hospital, Detroit, Michigan
1 shared publicationAshok Kondur
Wayne State University/Detroit Medical Center, Heart Hospital, Detroit, Michigan
1 shared publicationAshutosh Niraj
Detroit Medical Center, Detroit, Michigan
1 shared publicationCindy Grines
Wayne State University/Detroit Medical Center, Heart Hospital, Detroit, Michigan
1 shared publication
Latest Publications
- 18 April 2017
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 90 (4) , 576-581
Real‐world supported unprotected left main percutaneous coronary intervention with impella device; data from the USpella registry
Background: Patients with left main (LM) coronary artery disease are increasingly being treated with percutaneous revascularization (PCI). The safety, feasibility, and efficacy of unprotected LM intervention (ULMI) with hemodynamic support by Impella device have not been evaluated previously.Objective: Using a large retrospective single center database from the USpella registry, we evaluated the safety, feasibility, and potential benefits of periprocedural left ventricular assist with axial flow Impella 2.5 and Impella CP (Abiomed Inc. Danvers, Mass) during ULMI.Methods: We analyzed a total of 127 consecutive patients who received hemodynamic support with Impella (2.5 or CP) for ULMI from August 2008 to July 2015. Safety, feasibility and efficacy end points included procedural success rates, in‐hospital and 30‐day major adverse cardiovascular event (MACE) rates.Results: Among 127 patients who received hemodynamic support for ULMI (mean age 69.98 ± 10.7 years, 71% men, and mean left ventricular ejection fraction 28.74 ± 15.55%, Society of Thoracic Surgeons' mortality/morbidity 4/23%) the in‐hospital and 30 days mortality rates were 1.43% (2/140) and 2.1% (3/141), respectively. The average baseline and post PCI (residual) syntax scores were 31.4 and 7.86, respectively, (P < 0.001). Only one patient (0.8%) had vascular complication that required surgery; 2.36% (3/127) had hematoma and 3.9% (5/127) had bleeding that required transfusion.Conclusion: This large singe center retrospective evaluation of USpella registry substantiates and strongly supports the feasibility, safety, and hemodynamic usefulness of Impella device for ULMI with acceptable in‐hospital and 30‐day MACE rates.
- 18 April 2017
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 90 (4) , 576-581
Real‐world supported unprotected left main percutaneous coronary intervention with impella device; data from the USpella registry
Background: Patients with left main (LM) coronary artery disease are increasingly being treated with percutaneous revascularization (PCI). The safety, feasibility, and efficacy of unprotected LM intervention (ULMI) with hemodynamic support by Impella device have not been evaluated previously.Objective: Using a large retrospective single center database from the USpella registry, we evaluated the safety, feasibility, and potential benefits of periprocedural left ventricular assist with axial flow Impella 2.5 and Impella CP (Abiomed Inc. Danvers, Mass) during ULMI.Methods: We analyzed a total of 127 consecutive patients who received hemodynamic support with Impella (2.5 or CP) for ULMI from August 2008 to July 2015. Safety, feasibility and efficacy end points included procedural success rates, in‐hospital and 30‐day major adverse cardiovascular event (MACE) rates.Results: Among 127 patients who received hemodynamic support for ULMI (mean age 69.98 ± 10.7 years, 71% men, and mean left ventricular ejection fraction 28.74 ± 15.55%, Society of Thoracic Surgeons' mortality/morbidity 4/23%) the in‐hospital and 30 days mortality rates were 1.43% (2/140) and 2.1% (3/141), respectively. The average baseline and post PCI (residual) syntax scores were 31.4 and 7.86, respectively, (P < 0.001). Only one patient (0.8%) had vascular complication that required surgery; 2.36% (3/127) had hematoma and 3.9% (5/127) had bleeding that required transfusion.Conclusion: This large singe center retrospective evaluation of USpella registry substantiates and strongly supports the feasibility, safety, and hemodynamic usefulness of Impella device for ULMI with acceptable in‐hospital and 30‐day MACE rates.
- 26 March 2008
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 72 (1) , 36-44
Comparison of five‐year outcome in African Americans versus Caucasians following percutaneous coronary intervention
Background: Studies regarding short‐term outcomes after percutaneous coronary intervention (PCI) have reported no ethnic differences and data on long‐term follow‐up is conflicting and sparse. Methods: 730 consecutive patients (67% African American) undergoing PCI from January 1999 to December 2000 at a tertiary care center in Detroit, MI, were followed up. End points studied included either all cause mortality collected from Social Security Death Index or first hospital admission after the index procedure due to myocardial infarction(MI), congestive heart failure(CHF), and revascularization (PCI or coronary artery bypass graft surgery). Results: African‐Americans undergoing PCI had significant differences in baseline cardiovascular co‐morbidity and were more likely to present with acute myocardial infarction than Caucasians. On Kaplan Meier survival analysis and log rank test, each ethnic group had equivalent survival for cumulative end points upto 6‐month follow‐up, however longer follow‐up to 5 year was characterized by lower survival rate in African Americans compared to Caucasians (41% vs. 54%, log rank P 0.01). After adjustment for potential confounders, AA ethnicity (Adjusted HR 1.62, 95% CI 1.01–1.28, P 0.04) remained a predictor of adverse cardiac outcome (Death/MI/CHF) at five‐year follow‐up (Cox regression propensity adjusted hazard analysis). Conclusions: African American patients undergoing PCI had unfavorable baseline cardiovascular characteristics but comparable short‐term outcome compared to whites. However, at 5‐year follow‐up, African Americans had worse clinical outcome, higher incidence of acute myocardial infarction, congestive heart failure and significantly lower long‐term survival.
- 26 March 2008
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 72 (1) , 36-44
Comparison of five‐year outcome in African Americans versus Caucasians following percutaneous coronary intervention
Background: Studies regarding short‐term outcomes after percutaneous coronary intervention (PCI) have reported no ethnic differences and data on long‐term follow‐up is conflicting and sparse. Methods: 730 consecutive patients (67% African American) undergoing PCI from January 1999 to December 2000 at a tertiary care center in Detroit, MI, were followed up. End points studied included either all cause mortality collected from Social Security Death Index or first hospital admission after the index procedure due to myocardial infarction(MI), congestive heart failure(CHF), and revascularization (PCI or coronary artery bypass graft surgery). Results: African‐Americans undergoing PCI had significant differences in baseline cardiovascular co‐morbidity and were more likely to present with acute myocardial infarction than Caucasians. On Kaplan Meier survival analysis and log rank test, each ethnic group had equivalent survival for cumulative end points upto 6‐month follow‐up, however longer follow‐up to 5 year was characterized by lower survival rate in African Americans compared to Caucasians (41% vs. 54%, log rank P 0.01). After adjustment for potential confounders, AA ethnicity (Adjusted HR 1.62, 95% CI 1.01–1.28, P 0.04) remained a predictor of adverse cardiac outcome (Death/MI/CHF) at five‐year follow‐up (Cox regression propensity adjusted hazard analysis). Conclusions: African American patients undergoing PCI had unfavorable baseline cardiovascular characteristics but comparable short‐term outcome compared to whites. However, at 5‐year follow‐up, African Americans had worse clinical outcome, higher incidence of acute myocardial infarction, congestive heart failure and significantly lower long‐term survival.